Thai Pharmaceutical Manufacturers Assoc calls for the government to revoke the GPO's special privileges on hospitals buying from it
The special purchase procedures enjoyed by Thailand's Government Pharmaceutical Organization (GPO), the state drug company, must be revoked, in order to support free market competition and help local manufacturers survive amid fierce competition with foreign pharmaceutical companies, argued Chernporn Tengamnuay, president of the Thai Pharmaceutical Manufacturers Association (TPMA), reported by the local newspaper, The Nation.
"The GPO is now trying to improve its capacity to produce medical products and compete with private drugmakers. Who will gain from this?" he said at a TPMA-sponsored seminar titled The Right to Access Medicine and Problems That Need to Be Resolved.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
| Headless Content Management with Blaze